<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763735</url>
  </required_header>
  <id_info>
    <org_study_id>131271</org_study_id>
    <nct_id>NCT02763735</nct_id>
  </id_info>
  <brief_title>Right Ventricular Metabolism in Pulmonary Arterial Hypertension</brief_title>
  <official_title>Metabolic Intervention in the Right Ventricle in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use non-invasive imaging to determine the metabolic phenotype
      of the right ventricle in patients with pulmonary arterial hypertension across a spectrum of
      disease severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current medical therapy for pulmonary arterial hypertension (PAH) is aimed at reducing
      pulmonary vascular resistance (PVR) but not ameliorating right ventricular (RV) failure, the
      major cause of death. There are no RV-specific therapies currently available for PAH, in part
      because the pathophysiology of RV failure is poorly understood.

      The investigators hypothesize that the RV in PAH develops a distinct metabolic pattern
      characterized by increased glycolysis, impaired oxidative metabolism and lipid deposition,
      which are associated with RV failure.

      Specific Aim 1. To test the hypothesis that the RV in human PAH exhibits lipid deposition,
      increased glycolysis and impaired fatty acid oxidation. The investigators will measure RV
      oxidative metabolism and glycolysis in PAH patients and controls using positron emission
      tomography 11C acetate and [18F]fluoro-deoxy-D-glucose imaging and measure myocardial lipid
      accumulation using magnetic resonance spectroscopy imaging.

      Specific Aim 2. To test the hypothesis that an abnormal RV metabolic profile is associated
      with RV dysfunction and reduced exercise capacity in PAH. PET and MRS findings will be
      correlated with RV function, patient exercise capacity and a blood metabolic profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular oxygen consumption divided by the rate pressure product</measure>
    <time_frame>At time of C11 acetate PET scan</time_frame>
    <description>kmono divided by the rate pressure product (heart rate X systolic blood pressure)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right ventricular oxygen consumption (kmono)</measure>
    <time_frame>At time of C11 acetate PET scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular glucose uptake (standardized uptake value)</measure>
    <time_frame>At time of 18-FDG PET scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent myocardial triglyceride content</measure>
    <time_frame>At time of cardiac magnetic resonance imaging</time_frame>
    <description>Percent of myocardial triglyceride measured in the interventricular septum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with right ventricular function</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with six minute walk distance</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with plasma metabolic profile</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pulmonary Arterial Hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with idiopathic or heritable pulmonary arterial hypertension according to consensus guidelines exposed to C11 acetate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects without cardiopulmonary disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects without known cardiopulmonary disease exposed to C11 acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C acetate</intervention_name>
    <description>Radiopharmaceutical</description>
    <arm_group_label>Pulmonary Arterial Hypertension</arm_group_label>
    <arm_group_label>Subjects without cardiopulmonary disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heritable or idiopathic PAH

          -  18 years or older

          -  Able to give informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Type 1 diabetes mellitus

          -  Prednisone use

          -  PAH associated with any condition other than idiopathic or heritable

          -  Implanted ferromagnetic material incompatible with MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evan Brittain, MD</last_name>
    <phone>6153224382</phone>
    <email>evan.brittain@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Evan Brittain, MD, MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://medschool.vanderbilt.edu/pah/</url>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Evan Brittain</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>Right ventricle</keyword>
  <keyword>Right ventricular function</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Non-invasive imaging</keyword>
  <keyword>Healthy Subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

